Chordia Therapeutics (TSE:190A) EBIT: 円-1,456.15 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics EBIT?

Chordia Therapeutics TSE:190A -2.53% 11 EBIT is 円-1,456.15 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Chordia Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Feb. 2026 was 円-662.73 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was 円-1,456.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chordia Therapeutics's annualized ROC % for the quarter that ended in Feb. 2026 was -1,491.68%. Chordia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Chordia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -44.33%.

Chordia Therapeutics  (TSE:190A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chordia Therapeutics's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-1325.452 * ( 1 - 0% )/( (107.964 + 69.749)/ 2 )
=-1325.452/88.8565
=-1,491.68 %

where

Invested Capital(Q: Aug. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2681.349 - 148.69 - ( 2548.955 - max(0, 244.338 - 2669.033+2548.955))
=107.964

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2512.264 - 139.754 - ( 2447.76 - max(0, 197.24 - 2500.001+2447.76))
=69.749

Note: The Operating Income data used here is two times the semi-annual (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Chordia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1325.452/( ( (0 + max(-124.26, 0)) + (0 + max(-144.999, 0)) )/ 2 )
=-1325.452/( ( 0 + 0 )/ 2 )
=-1325.452/0
= %

where Working Capital is:

Working Capital(Q: Aug. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 120.078) - (148.69 + 0 + 95.648)
=-124.26

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 52.241) - (139.754 + 0 + 57.486)
=-144.999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Chordia Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-1456.149/3285.084
=-44.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics EBIT Related Terms

Chordia Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics EBIT Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
EBIT
-687.76 -1,829.55 212.06 -1,801.40 -1,789.78

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
EBIT Get a 7-Day Free Trial -809.66 -991.74 -996.36 -793.42 -662.73

TSE:190A vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Chordia Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's EV-to-EBIT falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-1,456.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-1,456.15 Mil mean?
Chordia Therapeutics (TSE:190A) has a EBIT of 円-1,456.15 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chordia Therapeutics.
Is Chordia Therapeutics' EBIT too high?
Chordia Therapeutics' current EBIT is 円-1,456.15 Mil. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' EBIT compare to VRTX and REGN?
Chordia Therapeutics' EBIT of 円-1,456.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chordia Therapeutics. Chordia Therapeutics's current EBIT is 円-1,456.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current EBIT of 円-1,456.15 Mil. The current EBIT is 円-1,456.15 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current EBIT is 円-1,456.15 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price